食管癌临床试验导航 | 海外癌症临床试验导航

即将招募 Phase 2 药物放疗

clinicaltrials.gov NCT05732662

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

适用疾病: Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
干预: SBRT，Cadonilimab
地点: 未列出
申办方: The First People's Hospital of Changzhou

正在招募 Phase 1 药物

clinicaltrials.gov NCT07085091

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

适用疾病: NSCLC (Advanced Non-small Cell Lung Cancer)；HNSCC；CRC (Colorectal Cancer)
干预: ALX2004，ALX2004，ALX2004
地点: United States
申办方: ALX Oncology Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07403136

Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Vebrekotuzumab，PD-1 antibody
地点: China
申办方: Fudan University

正在招募 Phase 2 药物

clinicaltrials.gov NCT06354218

Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

适用疾病: Esophageal Carcinoma
干预: Serplulimab
地点: China
申办方: The First Affiliated Hospital with Nanjing Medical University

即将招募阶段未标明手术/操作

clinicaltrials.gov NCT06979986

SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Cancer
干预: Endoscopic Submucosal Dissection with Systematically mediastinal Lymph Node Dissection，Endoscopic Submucosal Dissection without SLND
地点: 未列出
申办方: Fujian Cancer Hospital

正在招募 Phase 3 药物放疗

clinicaltrials.gov NCT04138212

Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Paclitaxel, Cisplatin，neoadjuvant chemoradiation therapy
地点: China
申办方: Henan Cancer Hospital

正在招募 Phase 3 放疗

clinicaltrials.gov NCT04328948

A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Chemoradiotherapy
地点: Japan
申办方: National Cancer Center, Japan

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06380816

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

适用疾病: Advanced Solid Tumours；Squamous Cell Carcinoma of Head and Neck；Carcinoma, Non-Small-Cell Lung
干预: UCB4594
地点: United Kingdom
申办方: Cancer Research UK

正在招募 Phase 2 药物

clinicaltrials.gov NCT06006650

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

适用疾病: Neoadjuvent；PD-1 Inhibitor；Chemotherapy
干预: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
地点: China
申办方: Tang-Du Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT06022861

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: LY01015，Fluorouracil，Cisplatin，Opdivo®
地点: China
申办方: Shandong Boan Biotechnology Co., Ltd

正在招募 Phase 3 药物放疗

clinicaltrials.gov NCT05043688

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

适用疾病: Resectable Esophageal Squamous Cell Carcinoma
干预: Camrelizumab，radiotherapy
地点: China
申办方: Zhigang Li

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06446726

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Tislelizumab，Low-dose radiotherapy，Nab-paclitaxel，Cisplatin
地点: China
申办方: Sichuan University

正在招募阶段未标明药物手术/操作放疗

clinicaltrials.gov NCT03734952

Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy

适用疾病: Radiation Oncology
干预: Neoadjuvant Radiotherapy Program:，Neoadjuvant chemotherapy Program，Esophagectomy program:，Postoperative radiotherapy program
地点: China
申办方: Fujian Medical University Union Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT07227168

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

适用疾病: Head and Neck Squamous Cell Carcinoma HNSCC；Non-Small Cell Lung Cancer NSCLC；Esophageal Cancer
干预: STRO-004，Pembrolizumab
地点: United States
申办方: Sutro Biopharma, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06489197

AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

适用疾病: ESCC；Advanced Esophageal Squamous Cell Carcinoma
干预: Ivonescimab combined with albumin paclitaxel and cisplatin
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06509568

Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Neoadjuvant chemoradiotherapy followed by immunotherapy，Neoadjuvant chemoimmunotherapy
地点: China
申办方: Zhejiang Cancer Hospital

即将招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT07251062

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

适用疾病: Esophageal Squamous Cell Carcinoma
干预: SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)，Investigator's choice of SOC，SYS6010+SG001
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06709417

A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Sintilimab，Chemotherapy，radiotherapy
地点: China
申办方: Shanghai Chest Hospital

正在招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT07162506

DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI

适用疾病: Esophageal Cancer
干预: Surgery，Radiotherapy，Chemotherapy，Immunotherapy
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT05144698

RAPA-201 Therapy of Solid Tumors

适用疾病: Solid Tumor；Small Cell and Non-small Cell Lung Cancer；Head and Neck Cancer
干预: RAPA-201 Rapamycin Resistant T Cells，Chemotherapy Prior to RAPA-201 Therapy，Pembrolizumab (PD-1 Blocking Antibody)
地点: United States
申办方: Rapa Therapeutics LLC

正在招募 Phase 2 药物

clinicaltrials.gov NCT06684600

Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Dalpiciclib + Pyrotinib
地点: China
申办方: Peking University

正在招募 Phase 2 药物

clinicaltrials.gov NCT07481058

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: KC1036，Toripalimab，Paclitaxel，Cisplatin
地点: China
申办方: Beijing Konruns Pharmaceutical Co., Ltd.

即将招募 Phase 2 药物

clinicaltrials.gov NCT06152978

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Sintilimab，Chemotherapy
地点: China
申办方: Fudan University

即将招募 Phase 2 放疗

clinicaltrials.gov NCT07164690

Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy

适用疾病: Esophageal Adenocarcinoma；Radiotherapy
干预: Low Dose Radiation Therapy
地点: 未列出
申办方: Fudan University

即将招募 Phase 3 药物

clinicaltrials.gov NCT07417735

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

适用疾病: Locally Advanced/Metastatic/Recurrent ESCC
干预: SYS6010，Investigator's Choice of Chemotherapy (Irinotecan hydrochloride，Paclitaxel，Docetaxel)
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT07405151

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

适用疾病: Oesophageal Squamous Cell Carcinoma
干预: I-DXd，Rescue Medication
地点: China，Czechia，Japan，Norway 等 4 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07061704

Oncolytic Virus in Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Cancer
干预: Oncolytic Virus: Administered via intratumoral injection (metastatic lesions in the neck or supraclavicular lymph nodes) once every 3 weeks, for a total of two to four doses.，Oncolytic Virus: Administered via intratumoral injection (primary lesions) once every 3 weeks, for a total of two to four doses.
地点: China
申办方: Sichuan University

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT05507411

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Neoadjuvant Radiotherapy，Neoadjuvant Chemotherapy，Immunotherapy
地点: China
申办方: Zhejiang Cancer Hospital

正在招募 Phase 3 联合产品

clinicaltrials.gov NCT04009265

Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: adjuvant treatment
地点: China
申办方: Fujian Medical University Union Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

适用疾病: Diffuse Astrocytoma, IDH-Mutant；Glioblastoma, IDH-wildtype；Brain Metastases, Adult
干预: NEO212 Oral Capsule，Ipilimumab，Pembrolizumab，Nivolumab
地点: United States
申办方: Neonc Technologies, Inc.

正在招募 Phase 3 手术/操作

clinicaltrials.gov NCT05547529

The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer

适用疾病: Esophageal Cancer
干预: Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.，Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
地点: Russia
申办方: Blokhin's Russian Cancer Research Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT07263919

Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

适用疾病: Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
干预: Cadonilimab (AK104)，Cisplatin，Paclitaxel
地点: China
申办方: Akeso

正在招募 Phase 2 联合产品

clinicaltrials.gov NCT06410651

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Cancer；Nimotuzumab；Chemoradiotherapy
干预: Nimotuzumab with chemoradiotherapy
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 3 药物

clinicaltrials.gov NCT04415853

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

适用疾病: Esophageal Cancer
干预: Lerotinib，Irinotecan/Tegafur
地点: China
申办方: Sunshine Lake Pharma Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT05984342

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Tislelizumab
地点: China
申办方: Affiliated Cancer Hospital of Shantou University Medical College

即将招募 Phase 2 联合产品其他手术/操作

clinicaltrials.gov NCT07505186

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma；Neoadjuvant Therapy
干预: Camrelizumab, Chemotherapy and Ivarmacitinib，Esophagectomy，Sample
地点: China
申办方: Second Affiliated Hospital, School of Medicine, Zhejiang University

即将招募 Phase 2 联合产品药物

clinicaltrials.gov NCT07469241

Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.

适用疾病: Advanced Esophageal Squamous Cell Carcinoma；Unresectable Esophageal Squamous Cell Carcinoma
干预: Concurrent chemoradiotherapy (cCRT)，Induced treatment
地点: 未列出
申办方: Fudan University

正在招募 Phase 3 联合产品药物

clinicaltrials.gov NCT06190782

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

适用疾病: Esophageal Squamous Cell Carcinoma；Oligometastatic Disease；Radiotherapy
干预: PD-1 inhibitor+/- chemotherapy combined with local therapy，systemic therapy alone
地点: China
申办方: Fudan University

即将招募 Phase 2 药物

clinicaltrials.gov NCT06426797

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

适用疾病: Locally Advanced Esophageal Squamous Cell Carcinoma
干预: Cadonilimab plus anlotinib
地点: 未列出
申办方: Peking University People's Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT06194734

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

适用疾病: Esophageal Squamous Cell Carcinoma
干预: KC1036，Irinotecan，Docetaxel，S-1
地点: China
申办方: Beijing Konruns Pharmaceutical Co., Ltd.

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06242470

A Study of MGC026 in Participants With Advanced Solid Tumors

适用疾病: Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MGC026 Dose Escalation，MGC026 Dose for Expansion
地点: United States，Australia，United Kingdom
申办方: MacroGenics

即将招募 Phase 2 药物

clinicaltrials.gov NCT06468644

Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: chemoradiotherapy （CRT）+sintilimab 1，CRT+sintilimab 2
地点: 未列出
申办方: Fujian Cancer Hospital

正在招募 Phase 2 生物制剂

clinicaltrials.gov NCT07530094

Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

适用疾病: Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
干预: Camrelizumab
地点: China
申办方: Ning Jiang, M.D./Ph.D.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07223424

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

适用疾病: Renal Cell Carcinoma；Non Small Cell Lung Cancer；Melanoma
干预: nivolumab，pembrolizumab
地点: United States
申办方: Diwakar Davar

正在招募 Phase 2 药物

clinicaltrials.gov NCT06356688

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Locally Advanced Esophageal Squamous Cell Carcinoma；Neoadjuvant Therapy
干预: Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab
地点: China
申办方: Sun Jing

即将招募 Phase 2 药物

clinicaltrials.gov NCT05996484

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

适用疾病: Esophageal Carcinoma；Neoadjuvant Therapy
干预: Toripalimab，Anlotinib hydrochloride，Albumin paclitaxel，Cisplatin
地点: 未列出
申办方: Nanfang Hospital, Southern Medical University

正在招募阶段未标明放疗

clinicaltrials.gov NCT04221893

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

适用疾病: Stage IV Esophageal Adenocarcinoma；Stage IV Esophageal Squamous Cell Carcinoma；Stage IV Gastric Cancer
干预: Radiation Therapy (RT)
地点: United States
申办方: University of California, San Francisco

正在招募 Phase 2 药物

clinicaltrials.gov NCT05182944

A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC

适用疾病: Esophageal Cancer
干预: A：non-pCR patients，B：non-pCR patients，A：pCR patients，B：pCR patients
地点: China
申办方: The First Affiliated Hospital of Zhengzhou University

正在招募 Phase 1, Phase 2 联合产品药物

clinicaltrials.gov NCT03526835

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

适用疾病: Advanced/Metastatic Solid Tumors；Colorectal Cancer；Gastric Cancer
干预: MCLA-158，MCLA-158 + Pembrolizumab，MCLA-158 + FOLFIRI，MCLA-158 + FOLFOX
地点: United States，Belgium，France，Netherlands 等 2 个
申办方: Merus B.V.

正在招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT07339488

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

适用疾病: Borderline Resectable Carcinoma；Unresectable Cancer；Esophageal Squamous Cell Carcinoma (ESCC)
干预: Intestinal Low Dose Radiotherapy-1Gy，PD-1/PD-L1 inhibitors，Chemotherapy，Surgery
地点: China
申办方: Chuangzhen Chen

正在招募 Phase 3 药物

clinicaltrials.gov NCT06644781

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Ifinatamab deruxtecan，Docetaxel，Paclitaxel，Irinotecan hydrochloride (HCl)
地点: United States，Belgium，China，France 等 9 个
申办方: Daiichi Sankyo

正在招募 Phase 1 药物

clinicaltrials.gov NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

适用疾病: Locally Advanced or Metastatic Solid Tumors；NSCLC；HNSCC
干预: Enzelkitug，Atezolizumab，Pembrolizumab
地点: United States，Australia，Belgium，Canada 等 6 个
申办方: Genentech, Inc.

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT07152678

Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Cancer；Esophageal Squamous Cell Carcinoma
干预: Nivolumab (240 mg)，Brachytherapy
地点: Taiwan
申办方: National Taiwan University Hospital

即将招募 Phase 2 生物制剂

clinicaltrials.gov NCT02490735

CIK in Treating Patients With Esophageal Cancer

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Cytokine-induced Killer Cells
地点: 未列出
申办方: The First People's Hospital of Changzhou

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06122493

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Tirelizumab，Nab paclitaxel，Carboplatin，Radiotherapy
地点: China
申办方: Ruijin Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT06681285

Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)

适用疾病: Esophageal Carcinoma
干预: Cadonilimab ;Anlotinib
地点: China
申办方: Hebei Medical University Fourth Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06329869

Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Sacituzumab govitecan
地点: Taiwan
申办方: National Taiwan University Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT07533305

Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

适用疾病: QL1706；ESCC；First-line Therapy
干预: QL1706 plus nab-paclitaxel and cisplatin
地点: 未列出
申办方: The First Affiliated Hospital of Henan University of Science and Technology

即将招募 Phase 2 药物

clinicaltrials.gov NCT07272291

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Toripalimab
地点: 未列出
申办方: Tianjin Medical University Cancer Institute and Hospital

即将招募 Phase 2 联合产品其他手术/操作

clinicaltrials.gov NCT07244978

Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma；Neoadjuvant Therapy
干预: Ivonescimab（AK112), Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy，Esophagectomy，Sample
地点: China
申办方: Second Affiliated Hospital, School of Medicine, Zhejiang University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07385001

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

适用疾病: Esophageal Squamous Cell Carcinoma；Ivonescimab；Neoadjuvant
干预: AK112，AK112，AK112 + Neoadjuvant chemotherapy
地点: China
申办方: Tang-Du Hospital

正在招募 Phase 2 放疗

clinicaltrials.gov NCT06603402

Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)；Immunotherapy
干预: low-dose involved-field radiotherapy combined with immunochemotherapy
地点: China
申办方: Sichuan University

正在招募 Phase 2 药物

clinicaltrials.gov NCT07452601

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Adebrelimab plus nab-paclitaxel and cisplatin
地点: China
申办方: Tang-Du Hospital

正在招募阶段未标明联合产品

clinicaltrials.gov NCT05775419

Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC

适用疾病: Esophageal Squamous Cell Carcinoma；Chemotherapy Effect；Side Effect of Drug
干预: Consolidation chemotherapy (4 courses)，Concurrent chemotherapy (2 courses)
地点: China
申办方: The First Affiliated Hospital with Nanjing Medical University

即将招募 Phase 3 药物

clinicaltrials.gov NCT07246330

Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Toripalimab
地点: 未列出
申办方: Tianjin Medical University Cancer Institute and Hospital

即将招募 Phase 2 药物放疗

clinicaltrials.gov NCT06464614

Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.

适用疾病: Esophageal Cancer
干预: Adebrelimab，Apatinib，Investigator chosen chemotherapy (ICC)，Radiotherapy
地点: China
申办方: The First Affiliated Hospital of Henan University of Science and Technology

即将招募 Phase 3 药物

clinicaltrials.gov NCT06952621

Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: 3 cycles (Toripalimab + chemotherapy)，3 cycles（DCF）
地点: China
申办方: Tang-Du Hospital

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT02972372

Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer

适用疾病: Esophagus Cancer
干预: CRT，surgery
地点: China
申办方: The First Affiliated Hospital of Henan University of Science and Technology

正在招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT06421376

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

适用疾病: Esophageal Cancer；Immunotherapy；Induction Therapy
干预: Cardonilizumab，Chemoradiotherapy ±immunotherapy，Radical surgery
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT07039162

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)；Locally Advanced Unresectable Esophageal Cancer
干预: Tislelizumab，Paclitaxel，Cisplatin，Radiation Therapy
地点: Taiwan
申办方: Ming-Yu Lien

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06601309

Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Serplulimab，Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)，Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)，Radiotherapy
地点: China
申办方: Fujian Medical University Union Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06403878

Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

适用疾病: Esophageal Cancer
干预: Carboplatin，Nab paclitaxel，Sintilimab
地点: China
申办方: Sichuan University

正在招募 Phase 3 生物制剂药物放疗

clinicaltrials.gov NCT04807673

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Pembrolizumab，Paclitaxel，Cisplatin，neoadjuvant chemoradiotherapy
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

即将招募阶段未标明手术/操作

clinicaltrials.gov NCT06012214

RAE Versus MIE in Patients With Esophageal Cancer After Neoadjuvant Therapy

适用疾病: Surgical Procedure, Unspecified
干预: ROBOTIC-ASSISTED ESOPHAGECTOMY
地点: China
申办方: Shanghai Chest Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06637163

Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy，Paclitaxel + Carboplatin + Radiotherapy
地点: China
申办方: Shanghai Zhongshan Hospital

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT05319730

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Paclitaxel，Irinotecan，Pembrolizumab，MK-4830
地点: United States，Brazil，Chile，China 等 10 个
申办方: Merck Sharp & Dohme LLC

即将招募 Phase 2 药物

clinicaltrials.gov NCT07531979

Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2

适用疾病: ESCC；Tislelizumab；Chemotherapy
干预: Tislelizumab，Becotatug Vedotin，Cisplatin，Tislelizumab
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06747585

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

适用疾病: Squamous Non-small-cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Cervical Squamous Cell Carcinoma
干预: ALE.P02
地点: United States，France，Hong Kong，Italy 等 4 个
申办方: Alentis Therapeutics AG

即将招募 Phase 2 药物

clinicaltrials.gov NCT06508229

Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Adebrelimab，albumin paclitaxel，Nedaplatin
地点: 未列出
申办方: Harbin Medical University

即将招募 Phase 2 药物

clinicaltrials.gov NCT07128693

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Sacituzumab Tirumotecan in combination with tislelizumab，Sacituzumab Tirumotecan in combination with anlotinib
地点: 未列出
申办方: The First Affiliated Hospital of Zhengzhou University

正在招募 Phase 3 药物手术/操作放疗

clinicaltrials.gov NCT04460352

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Neoadjuvant radiotherapy (arm A)，Carboplatin, paclitaxel，Esophagectomy，Neoadjuvant radiotherapy (arm B)
地点: Canada，Ireland，Norway，Sweden 等 1 个
申办方: Karolinska University Hospital

即将招募 Phase 4 药物

clinicaltrials.gov NCT06388135

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Serplulimab Combined With Nab-paclitaxel and Cisplatin，nab-paclitaxel，Cisplatin
地点: 未列出
申办方: Yang Jianjun, PhD

正在招募 Phase 1, Phase 2 药物放疗

clinicaltrials.gov NCT04278287

Chemoradiotherapy in Unresectable Esophageal Cancer

适用疾病: Esophageal Cancer；Chemoradiotherapy；Albumin-bound Paxlitaxel
干预: Radiotherapy，Albumin-Bound Paclitaxel，Cisplatin
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 2 联合产品

clinicaltrials.gov NCT06430658

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer

适用疾病: Esophagus Cancer
干预: Tislelizumab (BGB-A317) with chemoradiotherapy
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07109726

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

适用疾病: Breast Cancer；Endometrial Cancer；Ovarian Cancer
干预: TER-2013，Fulvestrant injection
地点: United States，Puerto Rico
申办方: Terremoto Biosciences Inc.

即将招募 Phase 2 放疗

clinicaltrials.gov NCT06143722

Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.

适用疾病: Advanced Esophageal Squamous Carcinoma With Oligometastases
干预: simultaneous with radiotherapy，synchronous with radiotherapy
地点: 未列出
申办方: West China Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06908382

Neoadjuvant QL1706 Therapy for ESCC

适用疾病: Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
干预: Iparomlimab and Tuvonralimab Injection
地点: China
申办方: Shandong Provincial Hospital

正在招募 Phase 1 药物手术/操作放疗

clinicaltrials.gov NCT07317609

Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Tislelizumab，Carboplatin，Nab-paclitaxel，Endoscopic resection
地点: China
申办方: Shanghai Zhongshan Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT05214222

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Advanced Esophageal Squamous Cell Carcinoma
干预: Anlotinib/Penpulimab/Chemotherapy，Penpulimab/Chemotherapy
地点: China
申办方: Nanfang Hospital, Southern Medical University

正在招募 Phase 2 药物

clinicaltrials.gov NCT07188103

Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Ivonescimab+Radiotherapy
地点: China
申办方: Anhui Provincial Hospital

正在招募 Phase 3 药物手术/操作放疗

clinicaltrials.gov NCT05357846

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

适用疾病: Squamous Cell Esophageal Carcinoma；Esophageal Cancer；Oesophageal Cancer
干预: Sintilimab，Preoperative radiotherapy，Paclitaxel，Cisplatin
地点: China
申办方: Sun Yat-sen University

正在招募 Phase 2 药物

clinicaltrials.gov NCT05738434

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

适用疾病: Esophageal Cancer by AJCC V8 Stage
干预: Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib，Camrelizumab+Chemotherapy→Camrelizumab
地点: China
申办方: The First Affiliated Hospital of Zhengzhou University

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06646588

Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Neoplasms
干预: Fruquintinib，Tislelizumab，Radiotherapy
地点: China
申办方: Hebei Medical University Fourth Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT06563869

Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: PEG-rhG-GSF
地点: China
申办方: The First Affiliated Hospital with Nanjing Medical University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07189871

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

适用疾病: Castration-Resistant Prostate Cancer (CRPC)；Colorectal Cancer；NSCLC (Non-small Cell Lung Cancer)
干预: 177Lu-BetaBart
地点: United States
申办方: Radiopharm Theranostics, Ltd

正在招募 Phase 2 药物

clinicaltrials.gov NCT06718205

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Cancer
干预: Nimotuzumab，Sintilimab，Paclitaxel-albumin，Cisplatin
地点: China
申办方: The First Affiliated Hospital of Zhengzhou University

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT07086469

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Toripalimab；Surufatinib；Neoadjuvant Immunochemotherapy
干预: Neoadjuvant immunochemotherapy，Surufatinib Administration，Concurrent Chemotherapy，Radiotherapy
地点: China
申办方: Sun Yat-sen University

正在招募 Phase 2 药物

clinicaltrials.gov NCT06190639

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: sintilimab
地点: China
申办方: Zhejiang Cancer Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT07638436

Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Adebrelimab Injection
地点: China
申办方: Sun Yat-sen University

即将招募 Phase 2 药物

clinicaltrials.gov NCT06903871

Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)

适用疾病: Esophageal Squamous Cell Carcinoma Stage II；Esophageal Squamous Cell Carcinoma Stage III
干预: TORIPALIMAB INJECTION(JS001 )
地点: China
申办方: Hebei Medical University Fourth Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT07503808

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

适用疾病: Esophageal Squamous Cell Carcinoma；High Grade Serous Ovarian Cancer；Head and Neck Squamous Cell Carcinoma
干预: IDE034
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 2 药物

clinicaltrials.gov NCT06354140

PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Tegafur
地点: China
申办方: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

正在招募 Phase 2 药物

clinicaltrials.gov NCT06663059

Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

适用疾病: Esophageal Cancer
干预: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle，Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle
地点: China
申办方: Tang-Du Hospital

正在招募阶段未标明放疗

clinicaltrials.gov NCT06596954

Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Cancer
干预: lymphocyte-sparing radiotherapy，conventional radiotherapy
地点: China
申办方: Ruijin Hospital

正在招募 Phase 3 药物放疗

clinicaltrials.gov NCT05919030

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Intensity-modulated radiotherapy (IMRT)，Tislelizumab，Cisplatin，Nab paclitaxel
地点: China
申办方: Renmin Hospital of Wuhan University

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT07038629

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

适用疾病: Esophageal Cancer
干预: S1，Iparomlimab，Radiation
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06463834

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Sintilimab
地点: China
申办方: Fujian Cancer Hospital

正在招募 Phase 2, Phase 3 药物手术/操作

clinicaltrials.gov NCT04973306

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

适用疾病: Esophageal Squamous Cell Carcinoma Stage II；Esophageal Squamous Cell Carcinoma Stage III
干预: Neoadjuvant Chemoradiotherapy，Tislelizumab，Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)
地点: China
申办方: Shanghai Zhongshan Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT06468670

Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: sintilimab，programmed death 1 monoclonal antibody
地点: 未列出
申办方: Fujian Cancer Hospital

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06764355

Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma

适用疾病: ESCC；Total Neoadjuvant Treatment；Pathological Complete Response
干预: Tislelizumab，Paclitaxel，Cisplatin，Chemoradiotherapy
地点: Taiwan
申办方: National Taiwan University Hospital

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06061146

Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC

适用疾病: Esophageal Cancer
干预: Arm A，Arm A，Arm A，Arm B
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06988956

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Nimotuzumab，Tegafur，radiotherapy
地点: China
申办方: The First Affiliated Hospital with Nanjing Medical University

正在招募 Phase 3 联合产品其他手术/操作

clinicaltrials.gov NCT04135664

Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Cancer
干预: esophagectomy，chemoradiation，active surveillance
地点: China
申办方: Shanghai Chest Hospital

正在招募 Phase 2 药物其他手术/操作

clinicaltrials.gov NCT06576973

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma；Neoadjuvant Treatment
干预: Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib，Esophagectomy，Collecting samples from participant
地点: China
申办方: Second Affiliated Hospital, School of Medicine, Zhejiang University

即将招募 Phase 2 手术/操作

clinicaltrials.gov NCT07376876

Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)；Esophageal Cancer
干预: Indocyanine green-guided omental shield anastomosis for cervical esophagogastric anastomosis
地点: China
申办方: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

正在招募 Phase 2 药物

clinicaltrials.gov NCT03736863

A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Cancer
干预: Apatinib+ SHR-1210（Camrelizumab），Apatinib+ SHR-1316（Adebrelimab），SHR-1316（Adebrelimab）+SHR-A2009
地点: China
申办方: The First Affiliated Hospital of Zhengzhou University

即将招募 Phase 3 药物放疗

clinicaltrials.gov NCT05244798

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Sintilimab，radiotherapy，Chemotherapy
地点: China
申办方: Sichuan Cancer Hospital and Research Institute

即将招募 Phase 2 药物

clinicaltrials.gov NCT07493993

Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

适用疾病: ESCC
干预: lparomlimab and Tuvonralimab Injection in Combination with Nab-Paclitaxel
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 2 其他放疗

clinicaltrials.gov NCT06272214

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

适用疾病: Adjuvant Radiotherapy
干预: Adjuvant radiotherapy，Observation
地点: China
申办方: Zhejiang Cancer Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT06598917

Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT

适用疾病: Locally Advanced Unresectable Esophageal Cancer
干预: S-1
地点: 未列出
申办方: China Medical University Hospital

正在招募阶段未标明药物

clinicaltrials.gov NCT07627347

Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)

适用疾病: ESCC
干预: anlotinib+bevacizumab
地点: China
申办方: Nanfang Hospital, Southern Medical University

正在招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT06690476

Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Dose escalation(IPM514 monotherapy)，Dose expansion (IPM514 combined with tislelizumab)，Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)
地点: China
申办方: Peking University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05937438

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

适用疾病: Esophageal Carcinoma
干预: Immune Checkpoint Inhibitors
地点: China
申办方: Anhui Provincial Hospital

正在招募 Phase 2 联合产品

clinicaltrials.gov NCT07016724

Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer

适用疾病: Esophageal Squamous Cell Carcinoma
干预: cadonilizumab combined with neoadjuvant radiochemotherapy，neoadjuvant radiochemotherapy
地点: China
申办方: The First Affiliated Hospital of Zhengzhou University

正在招募 Phase 2 药物

clinicaltrials.gov NCT07266493

Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma；Neoadjuvant Therapy
干预: Chemotherapy （Albumin bound paclitaxel and Carboplatin）
地点: China
申办方: Shanghai Zhongshan Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

适用疾病: Carcinoma, Non-Small Cell Lung；Squamous Cell Carcinoma of Head and Neck；HER2 Negative Breast Neoplasms
干预: sigvotatug vedotin，pembrolizumab，cisplatin，carboplatin
地点: United States，France，South Korea，Spain 等 3 个
申办方: Seagen, a wholly owned subsidiary of Pfizer

即将招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT07554456

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

适用疾病: Esophageal Squamous Cell Carcinoma
干预: BL-B01D1，Tislelizumab，5-Fluorouracil，Cisplatin
地点: China
申办方: Sichuan Baili Pharmaceutical Co., Ltd.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06753747

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophagus Cancer
干预: Palbociclib，Afatinib(30mg)，Afatinib(40mg)，Afatinib(RP2D)
地点: China
申办方: West China Hospital

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT06602843

Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
地点: China
申办方: Anhui Provincial Hospital

即将招募 Phase 3 联合产品药物手术/操作

clinicaltrials.gov NCT07629817

Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy，Radiation with Concurrent Chemotherapy，Radical Esophagectomy
地点: 未列出
申办方: Henan Cancer Hospital

正在招募 Phase 3 药物放疗

clinicaltrials.gov NCT06964568

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

适用疾病: Esophageal Carcinoma；Radiotherapy；Immunotherapy
干预: PD-1 inhibitor，Unlimited radiotherapy，TP regimen，TDLN-sparing radiotherapy
地点: China
申办方: Fudan University

正在招募 Phase 2 药物

clinicaltrials.gov NCT06769113

A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy

适用疾病: Esophageal Cancer
干预: HLX43
地点: China
申办方: Shanghai Henlius Biotech

即将招募 Phase 2 药物

clinicaltrials.gov NCT05896787

Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

适用疾病: Esophageal Squamous Cell Carcinoma
干预: AK104, nab-paclitaxel, carboplatin
地点: China
申办方: The First Affiliated Hospital of Zhengzhou University

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT05515315

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

适用疾病: Immunotherapy Esophagus Cancer
干预: Tislelizumab，Albumin paclitaxel，Nedaplatin，radiotherapy
地点: China
申办方: Fuzhou General Hospital

正在招募 Phase 2 生物制剂药物

clinicaltrials.gov NCT06535607

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

适用疾病: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)；Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)；Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
干预: Volrustomig，Cisplatin，Carboplatin，Paclitaxel
地点: United States，Australia，Brazil，Canada 等 8 个
申办方: AstraZeneca

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT05327517

Surgery or Chemoradiotherapy for Cervical Esophageal Cancer

适用疾病: Cervical Esophageal Cancer
干预: Esophagectomy
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

即将招募 Phase 3 药物

clinicaltrials.gov NCT07446335

A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Advanced Esophageal Squamous Cell Carcinoma
干预: anlotinib combined with benmelstobart，Toripalimab Combined with Chemotherapy
地点: China
申办方: The First Affiliated Hospital of Zhengzhou University

正在招募 Phase 1 药物

clinicaltrials.gov NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

适用疾病: Non Small Cell Lung Cancer；Lung Cancer；Breast Cancer
干预: BL-B01D1
地点: United States，France，Italy，Japan 等 1 个
申办方: SystImmune Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

适用疾病: Metastatic Solid Tumor；Recurrent Solid Tumor；Advanced Solid Tumor
干预: LY4052031
地点: United States，Australia，China，France 等 4 个
申办方: Eli Lilly and Company

正在招募 Phase 2 药物

clinicaltrials.gov NCT05563766

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

适用疾病: Esophageal Adenocarcinoma；Esophageal Squamous Cell Carcinoma；Gastroesophageal Junction Carcinoma
干预: Itraconazole
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05473156

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

适用疾病: Locally Advanced or Metastatic Solid Tumors；Non Small Cell Lung Cancer (NSCLC)；Head and Neck Squamous Cell Carcinoma (HNSCC)
干预: AP203，AP203
地点: Taiwan
申办方: AP Biosciences Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

适用疾病: Head and Neck Carcinoma；Adenoid Cystic Carcinoma；Lung Cancer
干预: VMD-928 100 mg Tablet，VMD-928 Tablet and Pembrolizumab (200 mg)
地点: United States，Puerto Rico
申办方: VM Oncology, LLC

即将招募 Phase 3 药物

clinicaltrials.gov NCT07621601

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: HS-20093 for Injection，Irinotecan; Paclitaxel; Docetaxel
地点: 未列出
申办方: Hansoh BioMedical R&D Company

正在招募 Phase 1 药物

clinicaltrials.gov NCT05005403

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

适用疾病: Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Micro Satellite Stable Colorectal Cancer
干预: Azirkitug，Budigalimab，Bevacizumab，Telisotuzumab Adizutecan
地点: United States，Canada，Israel，Japan 等 2 个
申办方: AbbVie

正在招募 Phase 2 药物

clinicaltrials.gov NCT07266480

Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.

适用疾病: Squamous Oesophageal Cancer
干预: Adebrelizumab
地点: China
申办方: Hebei Medical University Fourth Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT06852456

QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

适用疾病: Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
干预: Iparomlimab and Tuvonralimab (QL1706)Injection，Paclitaxel，Cisplatin
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

正在招募 Phase 2, Phase 3 药物放疗

clinicaltrials.gov NCT06907602

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Locally Advanced Esophageal Squamous Cell Carcinoma
干预: Chemotherapy，Immunotherapy (Pembrolizumab)，radiotherapy
地点: China
申办方: Peking Union Medical College Hospital

即将招募 Phase 2 药物其他手术/操作

clinicaltrials.gov NCT06861894

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Adebrelimab and nab-paclitaxel and carboplatin，Radiation，standard oesophagectomy，active surveillance
地点: China
申办方: Zhigang Li

正在招募 Phase 2 药物

clinicaltrials.gov NCT06885814

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Adebrelimab: 20mg/kg day1, Q3W, 3 times
地点: China
申办方: Nanfang Hospital, Southern Medical University

即将招募阶段未标明手术/操作

clinicaltrials.gov NCT05420480

Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Two-Field lymph node dissection，Three-Field lymph node dissection，Three-Field lymph node dissection
地点: China
申办方: Shanghai Zhongshan Hospital

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06912074

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Induction chemoimmunotherapy，Hypofractionated Radiation Therapy，Conventional Fractionated Radiation Therapy，Concurrent Chemotherapy
地点: China
申办方: Sun Yat-sen University

正在招募 Phase 3 药物放疗

clinicaltrials.gov NCT06676449

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

适用疾病: Esophageal Carcinoma；Radiotherapy；Immunotherapy
干预: Immunotherapy，chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens，TDLN-sparing RT
地点: China
申办方: Fudan University

即将招募 Phase 2 药物

clinicaltrials.gov NCT06814158

Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

适用疾病: Esophageal Squamour Cell Cancer
干预: Ivonescimab Combined With Chemotherapy
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT04280822

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

适用疾病: Esophageal Cancer；Surgery；Neoadjuvant Treatment
干预: Neoadjuvant immunochemotherapy
地点: China
申办方: Henan Cancer Hospital

即将招募 Phase 2 药物放疗

clinicaltrials.gov NCT07678580

Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Albumin-bound paclitaxel，Low-dose Short-course Radiotherapy，High-dose Short-course Radiotherapy，Tislelizumab Combined With Chemotherapy for 3 cycles
地点: China
申办方: Tang-Du Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05910827

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

适用疾病: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer；Advanced Head and Neck Squamous Cell Carcinoma；Advanced Esophageal Squamous Cell Carcinoma
干预: HMBD-001，Docetaxel，Cetuximab
地点: Australia，Moldova，Singapore，South Korea 等 1 个
申办方: Hummingbird Bioscience

正在招募 Phase 1 药物

clinicaltrials.gov NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

适用疾病: NSCLC Adenocarcinoma；Gastroesophageal Cancer (GC)；Gastric Adenocarcinoma
干预: IDE892，IDE397
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 2 药物

clinicaltrials.gov NCT07290010

The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Iparomlimab and Tuvonralimab combined with chemotherapy
地点: China
申办方: Hebei Medical University Fourth Hospital

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT03964753

Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Nab-paclitaxel and Cisplatin，surgery
地点: China
申办方: Hebei Medical University Fourth Hospital

即将招募 Phase 3 药物

clinicaltrials.gov NCT06501664

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

适用疾病: Esophageal Cancer
干预: liposomal irinotecan，5-FU，LV，Irinotecan
地点: 未列出
申办方: Rui-hua Xu, MD, PhD

即将招募 Phase 2 药物

clinicaltrials.gov NCT07688291

A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy

适用疾病: Esophageal Squamous Carcinoma Cell
干预: PD-1/IL-2α-bias bispecific antibody fusion protein
地点: China
申办方: Beijing GoBroad Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06422403

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

适用疾病: Carcinoma, Hepatocellular；Gastric Adenocarcinoma；GastroEsophageal Cancer
干预: Extended Dosing Interval - A，Extended Dosing Interval - B，Extended Dosing Interval - C，Standard of Care - A
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 2 药物

clinicaltrials.gov NCT07595770

Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
地点: China
申办方: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

即将招募阶段未标明药物其他

clinicaltrials.gov NCT07067450

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab)，Observation
地点: 未列出
申办方: Sichuan University

即将招募 Phase 1 药物放疗

clinicaltrials.gov NCT07034118

Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study

适用疾病: Esophageal Carcinoma
干预: Proton radiotherapy，Immune Checkpoint Inhibitors
地点: China
申办方: Anhui Provincial Hospital

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT03740256

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

适用疾病: Bladder Cancer；Head and Neck Squamous Cell Carcinoma；Cancer of the Salivary Gland
干预: CAdVEC
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT05978193

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma；Esophageal Cancer；Metastatic Esophageal Squamous Cell Carcinoma
干预: LDRT+CFRT，Immunotherapy，Chemotherapy
地点: China
申办方: Shanghai Chest Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT05281003

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Pembrolizumab，Paclitaxel，Cisplatin
地点: China
申办方: Fudan University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06943521

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Non-small Cell Lung Cancer (NSCLC)；Esophageal Cancer
干预: MT-4561
地点: United States，Japan
申办方: Tanabe Pharma America, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07484724

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Advanced Esophageal Squamous Cell Carcinoma
干预: JS212，JS001，5-FU
地点: China
申办方: Shanghai Junshi Bioscience Co., Ltd.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Clear Cell Renal Cell Carcinoma
干预: MDNA11，Pembrolizumab (KEYTRUDA®)
地点: United States，Australia，Canada，Ireland 等 3 个
申办方: Medicenna Therapeutics, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06339619

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

适用疾病: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
干预: Adebrelimab，Apatinib，Tegafur
地点: China
申办方: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

即将招募 Phase 2 药物

clinicaltrials.gov NCT07019181

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

适用疾病: Esophagus Cancer
干预: Tislelizumab，albumin-bound paclitaxel，Nedaplatin
地点: 未列出
申办方: The First Affiliated Hospital of Xiamen University

正在招募 Phase 2 药物

clinicaltrials.gov NCT06512428

A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Advanced Esophageal Squamous Cell Carcinoma
干预: simmitinib plus irinotecan liposome，irinotecan liposome，irinotecan
地点: China
申办方: Shanghai Runshi Pharmaceutical Technology Co., Ltd

正在招募阶段未标明药物放疗

clinicaltrials.gov NCT04481256

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY

适用疾病: Carcinoma, Squamous Cell；Oesophageal Cancer
干预: External beam radiotherapy，Bintrafusp alfa，Paclitaxel，Carboplatin
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT07622797

Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

适用疾病: Late-stage Resectable Esophageal Squamous Carcinoma
干预: Camrelizumab (anti-PD-1 inhibitor)，Albumin-Bound Paclitaxel /nab-Paclitaxel，Carboplatin，Capecitabine
地点: China
申办方: The First Affiliated Hospital of Henan University of Science and Technology

正在招募阶段未标明药物

clinicaltrials.gov NCT04174079

Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma

适用疾病: Thoracic Esophageal Squamous Cell Carcinoma
干预: chemotherapy
地点: China
申办方: Sun Yat-sen University

即将招募 Phase 2 药物

clinicaltrials.gov NCT07490002

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

适用疾病: Esophageal Squamous Carcinoma
干预: Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel
地点: 未列出
申办方: Changhai Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT07177794

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

适用疾病: Esophageal Cancer；Chemoradiotherapy
干预: toripalimab，capecitabine
地点: China
申办方: Sun Yat-sen University

正在招募 Phase 3 药物

clinicaltrials.gov NCT05078047

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

适用疾病: Lung Cancer Metastatic；Renal Cell Carcinoma；Head and Neck Cancer
干预: Reduced dose intensity of IO
地点: France
申办方: UNICANCER

即将招募 Phase 2 药物

clinicaltrials.gov NCT06588335

BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: BTLA inhibitor (JS004)，Toripalimab，Paclitaxel, Cisplatin
地点: 未列出
申办方: Henan Provincial People's Hospital

正在招募阶段未标明放疗

clinicaltrials.gov NCT05760391

A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.

适用疾病: Metastatic Esophageal Squamous Cell Carcinoma
干预: Radiotherapy
地点: China
申办方: Fudan University

正在招募 Phase 2 药物

clinicaltrials.gov NCT06304350

Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Cancer
干预: Combination of pembrolizumab and platinum containing dual drugs
地点: China
申办方: Tongji University

正在招募 Phase 2 药物

clinicaltrials.gov NCT06843889

A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

适用疾病: Locally Advanced Esophageal Squamous Cell Carcinoma
干预: Toripalimab (240mg day1, Q3W*3cycle)
地点: China
申办方: Nanfang Hospital, Southern Medical University

正在招募 Phase 3 药物

clinicaltrials.gov NCT07463573

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: QLC5508，Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride)
地点: China
申办方: Qilu Pharmaceutical Co., Ltd.

正在招募 Phase 1, Phase 2 药物放疗

clinicaltrials.gov NCT06173986

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

适用疾病: Esophageal Squamous Cell Carcinoma；Unresectable Locally Advanced Esophageal Cancer
干预: PD-1inhibitor，nab-paclitaxel + cisplatin，Radiotherapy
地点: China
申办方: Shanghai Chest Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT07284186

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

适用疾病: Esophageal Squamous Cell Carcinoma；Gastric Adenocarcinoma；Gastric Squamous Cell Carcinoma
干预: PLX-61639
地点: United States
申办方: Plexium, Inc.

即将招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT07653451

Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Afatinib + Toripalimab，Dalpiciclib + Pyrotinib，Camrelizumab + Apatinib
地点: 未列出
申办方: Peking University Cancer Hospital & Institute

正在招募 Phase 2 药物

clinicaltrials.gov NCT06056336

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma；Neoadjuvant Chemoimmunotherapy；Adjuvant Therapy
干预: Tislelizumab
地点: China
申办方: Guo Xufeng

正在招募 Phase 2 药物

clinicaltrials.gov NCT06498752

MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer

适用疾病: Esophageal Cancer
干预: PD-1 monoclonal antibody consolidation therapy
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

即将招募 Phase 2 药物

clinicaltrials.gov NCT07112833

A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

适用疾病: Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
干预: Induction stage：Adebrelimab+TC；Treatment stage: TC/PF+ radiation therapy；Maintenance stage: Adebrelimab
地点: China
申办方: Hebei Medical University Fourth Hospital

即将招募 Phase 3 药物

clinicaltrials.gov NCT06656091

A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma

适用疾病: Advanced Oesophageal Squamous Cell Carcinoma
干预: simmitinib，investigator's choice of chemotherapy,include docetaxel or irinotecan.
地点: 未列出
申办方: Shanghai Runshi Pharmaceutical Technology Co., Ltd

即将招募 Phase 2 药物

clinicaltrials.gov NCT07686926

Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Becotatug Vedotin，Tislelizumab，Lenvatinib
地点: 未列出
申办方: Tianjin Medical University Cancer Institute and Hospital

即将招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT07154108

Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer

适用疾病: Esophageal Cancer；Head and Neck Cancer (H&Amp;Amp;Amp;N)
干预: recombinant human endostatin adenovirus，PD-1 Inhibitor
地点: China
申办方: Sichuan University

正在招募 Phase 2 药物

clinicaltrials.gov NCT06869213

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma

适用疾病: Esophageal Cancer (EsC)
干预: Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin
地点: China
申办方: Peking University Cancer Hospital & Institute

正在招募 Phase 1 药物

clinicaltrials.gov NCT07182149

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

适用疾病: HNSCC；ESCC；Esophageal Adenocarcinoma
干预: NRM-823
地点: United States
申办方: Normunity AccelCo, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT04114136

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

适用疾病: Melanoma；NSCLC；Hepatocellular Carcinoma
干预: Nivolumab or Pembrolizumab (dependent upon approved indication)，Metformin，Rosiglitazone
地点: United States
申办方: Dan Zandberg

即将招募 Phase 2 药物

clinicaltrials.gov NCT07049185

QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: QL1706 Plus Celecoxib Group
地点: 未列出
申办方: Peking University Cancer Hospital & Institute

正在招募 Phase 2 联合产品

clinicaltrials.gov NCT06429839

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

适用疾病: Esophageal Cancer；Nimotuzumab；Chemoradiotherapy
干预: Nimotuzumab with chemoradiotherapy
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 2 药物

clinicaltrials.gov NCT07205731

Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1
地点: France
申办方: University Hospital, Clermont-Ferrand

即将招募 Phase 2 药物

clinicaltrials.gov NCT06599775

Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer

适用疾病: Resectable Esophageal Squamous Cell Carcinoma
干预: Adebrelimab injection，Albumin-Bound Paclitaxel，Carboplatin injection
地点: 未列出
申办方: Shanghai Zhongshan Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06385730

Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)

适用疾病: Esophageal Cancer
干预: neoadjuvant anti-PD-1，neoadjuvant anti-PD-1 with LDRT
地点: China
申办方: Shanghai Chest Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT07403435

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Serplulimab
地点: China
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

即将招募 Phase 2 药物

clinicaltrials.gov NCT06487702

A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium
地点: China
申办方: Rui-hua Xu, MD, PhD

正在招募 Phase 2 药物

clinicaltrials.gov NCT07559045

Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy)，Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy)
地点: China
申办方: Second Affiliated Hospital of Zunyi Medical University

即将招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT07046221

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

适用疾病: Esophagus Cancer
干预: Tislelizumab，Albumin-Bound Paclitaxel，cis-platinum，Surgery
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 3 药物

clinicaltrials.gov NCT07487896

A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy

适用疾病: Advanced Esophageal Squamous Cell Carcinoma
干预: YL201，Paclitaxel，Docetaxel，Irinotecan
地点: China
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT06138028

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

适用疾病: Metastatic Esophageal Squamous Cell Carcinoma
干预: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
地点: China
申办方: Qingdao Central Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06452602

Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.

适用疾病: Esophageal Cancer
干预: Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy，Induction immunochemotherapy followed by concurrent chemoradiotherapy
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT04018872

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

适用疾病: Esophagus Adenocarcinoma；Esophagus Squamous Cell Carcinoma；Gastroesophageal Junction Adenocarcinoma
干预: Itraconazole
地点: United States
申办方: Dallas VA Medical Center

即将招募 Phase 2 药物

clinicaltrials.gov NCT07623642

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

适用疾病: Uterine Cervical Neoplasms；Triple Negative Breast Neoplasms；Prostatic Neoplasms
干预: GV20-0251，anti-PD-1 monoclonal antibodies
地点: China
申办方: GV20 Therapeutics

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06187597

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)

适用疾病: Locally Advanced Esophageal Squamous Cell Carcinoma
干预: S-1，Toripalimab，Intensity-modulated radiotherapy
地点: China
申办方: Sun Yat-sen University

正在招募 Phase 2 药物

clinicaltrials.gov NCT07437898

Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Adebrelimab，chemotherapy
地点: China
申办方: The Affiliated Hospital of Putian University

正在招募阶段未标明药物放疗

clinicaltrials.gov NCT04519905

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

适用疾病: Esophageal Squamous Cell Carcinoma；Chemoradiotherapy；Survival
干预: Paclitaxel plus carboplatin，radiotherapy
地点: China
申办方: Fudan University

即将招募 Phase 1, Phase 2 药物放疗

clinicaltrials.gov NCT06136988

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

适用疾病: Locally Advanced Unresectable Esophageal Squamous Carcinoma
干预: Docetaxel for Injection (Albumin-bound)，SG001，Cisplatin for injection，Paclitaxel
地点: China
申办方: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

即将招募 Phase 1 生物制剂

clinicaltrials.gov NCT07203898

A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.

适用疾病: Esophageal Squamous Cell Carcinoma
干预: IPM514
地点: 未列出
申办方: Beijing Immupeutics Medicine Technology Limited

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06746961

Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)
干预: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)，Lenvatinib
地点: 未列出
申办方: The First Affiliated Hospital of Zhengzhou University

正在招募 Phase 2 药物

clinicaltrials.gov NCT07554521

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

适用疾病: Advanced Unresectable Gastric Adenocarcinoma；Esophageal Squamous Cell Carcinoma；Advanced Gastroesophageal Adenocarcinoma
干预: Tislelizumab，Capecitabine，5-fluorouracil (5-FU)，Oxaliplatin
地点: United States
申办方: BeOne Medicines

正在招募 Phase 1 药物

clinicaltrials.gov NCT07390838

A Study of SH009 Injection in Patients With Advanced Solid Tumors.

适用疾病: Liver Cancer (Locally Advanced or Metastatic)；Lung Cancer (NSCLC)；Head and Neck Cancer Squamous Cell Carcinoma
干预: SH009
地点: China
申办方: Nanjing Sanhome Pharmaceutical, Co., Ltd.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06510660

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

适用疾病: Esophageal Squamous Cell Carcinoma；Immunotherapy；Biomarkers
干预: adebrelimab
地点: China
申办方: Fujian Medical University Union Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT05208762

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

适用疾病: Carcinoma, Non-Small-Cell Lung；Squamous Cell Carcinoma of the Head and Neck；Esophageal Squamous Cell Carcinoma
干预: PF-08046054，pembrolizumab
地点: United States，Belgium，Canada，China 等 7 个
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募 Phase 2, Phase 3 药物放疗

clinicaltrials.gov NCT06354530

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Neoadjuvant Therapy；Esophageal Squamous Cell Carcinoma
干预: anlotinib，Thoracic radiotherapy
地点: China
申办方: Army Medical Center of PLA

正在招募 Phase 1 药物

clinicaltrials.gov NCT06545331

Study of XB010 in Subjects With Solid Tumors

适用疾病: Locally Advanced or Metastatic Solid Tumors；Esophageal Squamous Cell Cancer；Head and Neck Squamous Cell Cancer
干预: XB010，Pembrolizumab
地点: United States，United Kingdom
申办方: Exelixis

正在招募 Phase 2 药物

clinicaltrials.gov NCT07457528

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

适用疾病: Resectable Esophageal Squamous Cell Carcinoma
干预: HLX10，Chemotherapy，Nimotuzumab
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT06780111

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Pembrolizumab，I-DXd，Leucovorin，Levoleucovorin
地点: United States，Brazil，Chile，China 等 11 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 1 药物

clinicaltrials.gov NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

适用疾病: Advanced/Metastatic Solid Tumors；Bladder Cancer；Urothelial Carcinoma
干预: PF-08046876
地点: United States，Canada，Puerto Rico，Spain 等 1 个
申办方: Pfizer

正在招募 Phase 2 药物

clinicaltrials.gov NCT05252078

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

适用疾病: Esophageal Squamous Cell Carcinoma；Esophageal Neoplasms；Esophageal Diseases
干预: Anlotinib hydrochloride，TQB2450
地点: China
申办方: Jiangxi Provincial Cancer Hospital

正在招募 Phase 2 生物制剂

clinicaltrials.gov NCT06675201

Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma (ESCC)；Neoantigen-loaded Dendritic Cell Vaccine；Immune Checkpoint Inhibitors (ICIs)
干预: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
地点: China
申办方: Sichuan University

正在招募 Phase 1 药物

clinicaltrials.gov NCT07217171

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

适用疾病: Bladder Cancer；Squamous Cell Carcinoma of the Lung；Esophageal Squamous Cell Carcinoma
干预: EVOLVE104，EVOLVE104
地点: United States
申办方: EvolveImmune United, Inc

即将招募 Phase 2 药物

clinicaltrials.gov NCT07191977

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamour Cell Cancer
干预: Camrelizumab，Palbociclib
地点: 未列出
申办方: West China Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06413342

Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Cancer；Chemoradiotherapy；Sintilimab
干预: Sintilimab
地点: China
申办方: Zhejiang Cancer Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT06703047

Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: ATRA+pd-1+chemo，placebo+PD-1+chemo
地点: 未列出
申办方: Fudan University

正在招募 Phase 3 药物

clinicaltrials.gov NCT05495152

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Sintilimab
地点: China
申办方: Henan Cancer Hospital

即将招募 Phase 1 药物

clinicaltrials.gov NCT06491134

Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Liposomal Irinotecan Hydrochloride
地点: 未列出
申办方: Hebei Medical University Fourth Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT06178211

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Immunotherapy: Adebrelimab，chemotherapy: carboplatin plus nab-paclitaxel
地点: China
申办方: Shanghai Chest Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT06692270

Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma

适用疾病: Esophagus Cancer
干预: Tislelizumab
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT07618910

Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC

适用疾病: Esophageal Squamous Cell Carcinoma
干预: Retlirafusp alfa，Nab paclitaxel，Cisplatin for injection
地点: China
申办方: Tang-Du Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06846346

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

适用疾病: Metastatic Esophageal Adenocarcinoma；Advanced Esophageal Adenocarcinoma；Metastatic Gastric Adenocarcinoma
干预: Ivonescimab，FOLFOX regimen，Irinotecan，Paclitaxel
地点: France
申办方: UNICANCER

正在招募阶段未标明放疗

clinicaltrials.gov NCT05370144

A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma

适用疾病: Esophageal Cancer
干预: Hypofractionated radiotherapy
地点: Canada
申办方: AHS Cancer Control Alberta

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

即将招募 Phase 2 药物

clinicaltrials.gov NCT06469060

Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction

适用疾病: Esophageal Cancer
干预: neoadjuvant anti-PD-1 with DOC chemotherapy
地点: China
申办方: Shanghai Chest Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT05965479

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

适用疾病: Gastrooesophageal Cancer
干预: Trastuzumab deruxtecan
地点: United Kingdom
申办方: University of Southampton

即将招募 Phase 2 药物

clinicaltrials.gov NCT07233850

A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

适用疾病: Gastric/Gastroesophageal Junction Adenocarcinoma；Metastatic Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: SSGJ-706+XELOX，SSGJ-706+Bevacizumab+XELOX，SSGJ-706+AG，SSGJ-706+TP
地点: China
申办方: Shenyang Sunshine Pharmaceutical Co., LTD.

正在招募 Phase 2 药物

clinicaltrials.gov NCT05476796

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

适用疾病: Gastric Adenocarcinoma；Esophagus Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma
干预: Trifluridine/Tipiracil，Oxaliplatin，FOLFOX regimen，Nivolumab
地点: France
申办方: UNICANCER

即将招募 Phase 2 生物制剂联合产品药物

clinicaltrials.gov NCT07059611

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

适用疾病: Gastric Adenocarcinoma；Esophageal Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma
干预: RP2，5-Fluorouracil，Leucovorin，Oxaliplatin
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募 Phase 4 药物手术/操作

clinicaltrials.gov NCT06594744

Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC

适用疾病: Hepatocellular Carcinoma (HCC)；Esophageal Varices
干预: Endoscopic variceal ligation，Carvedilol
地点: Taiwan
申办方: Taipei Veterans General Hospital, Taiwan

正在招募 Phase 1 放疗

clinicaltrials.gov NCT07359443

Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma

适用疾病: Esophageal Adenocarcinoma；Esophageal Adenocarcinoma (EAC)；Adenocarcinoma - Gastroesophageal Junction (GEJ)
干预: MRI guided radiotherapy
地点: Netherlands
申办方: UMC Utrecht

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT05753748

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

适用疾病: Barretts Esophagus With Dysplasia；Barrett Esophagus；Esophageal Adenocarcinoma
干预: Endoscopic Eradication Therapy
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 1 药物

clinicaltrials.gov NCT07213791

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

适用疾病: Ovarian Neoplasms；Breast Neoplasms；Pancreatic Intraductal Neoplasms
干预: LY4337713
地点: United States，China，Germany，Japan 等 1 个
申办方: Eli Lilly and Company

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT07221149

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

适用疾病: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
干预: Pumitamig，Folfox，Capox，Nivolumab
地点: United States，Argentina，Australia，Brazil 等 17 个
申办方: Bristol-Myers Squibb

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07341737

SL-28 for Advanced Solid Tumours

适用疾病: Head & Neck Cancer；Pancreas Carcinoma；Pancreas Cancer, Metastatic
干预: SL-28，SL-28，SL-28
地点: Australia
申办方: Second Life Therapeutics

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT03539822

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

适用疾病: Gastric Cancer；Esophageal Adenocarcinoma；Hepatocellular Carcinoma
干预: Cabozantinib，Durvalumab，Tremelimumab
地点: United States
申办方: Anwaar Saeed

正在招募 Phase 2 药物

clinicaltrials.gov NCT07102901

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

适用疾病: Advanced Gastric Cancer；Metastatic Gastric Cancer；Gastroesophageal Junction Adenocarcinoma
干预: SHR2554 Tablets，SHR-A1811 Injection，SHR-A1904 Injection，SHR-1701 Injection
地点: China
申办方: Jiangsu HengRui Medicine Co., Ltd.

即将招募 Phase 2 药物

clinicaltrials.gov NCT07625930

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial

适用疾病: Gastroesophageal Adenocarcinoma
干预: SOC neoadjuvant FLOT (or FLOT-D) + simvastatin，SOC neoadjuvant FLOT (or FLOT-D)
地点: Canada
申办方: McGill University Health Centre/Research Institute of the McGill University Health Centre

即将招募 Phase 2 药物

clinicaltrials.gov NCT06447636

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

适用疾病: Gastric Cancer；Gastro Esophageal Junction Cancer
干预: Surufatinib，Sintilimab，Oxaliplatin，S1
地点: China
申办方: Fudan University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06324357

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

适用疾病: Metastatic Breast Cancer；Metastatic Gastric Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma
干预: Zongertinib，Trastuzumab deruxtecan，Trastuzumab emtansine，Trastuzumab
地点: United States，Belgium，China，France 等 6 个
申办方: Boehringer Ingelheim

正在招募 Phase 1 药物

clinicaltrials.gov NCT07021066

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

适用疾病: Gastric Adenocarcinoma；Advanced Pancreatic Ductal Adenocarcinoma；Esophageal Adenocarcinoma
干预: BL-M05D1
地点: United States
申办方: SystImmune Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07488676

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

适用疾病: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma；Pancreatic Adenocarcinoma
干预: ASP546C
地点: United States，Japan
申办方: Astellas Pharma Global Development, Inc.

即将招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT06748872

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

适用疾病: Epithelial Ovarian Cancer；Gastro-esophageal Junction Cancer；Soft Tissue Sarcoma (STS)
干预: Lymphodepletion，TCR-T cells (MDG1015)
地点: United States
申办方: Medigene AG

即将招募 Phase 2 药物

clinicaltrials.gov NCT07603375

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

适用疾病: Esophageal Adenocarcinoma
干预: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
地点: United States
申办方: Duke University

正在招募 Phase 2, Phase 3 生物制剂药物

clinicaltrials.gov NCT07392892

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

适用疾病: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma；Metastatic Gastric Cancer；Gastroesophageal Junction Cancer
干预: PF-08634404，Chemotherapy，Nivolumab
地点: United States，China，Israel，Japan 等 2 个
申办方: Pfizer

正在招募 Phase 2 药物

clinicaltrials.gov NCT04150640

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

适用疾病: Esophageal Adenocarcinoma；Gastric Adenocarcinoma
干预: Nal-IRI，Oxaliplatin，5-FU，Trastuzumab
地点: United States
申办方: University of Wisconsin, Madison

即将招募 Phase 1 生物制剂药物手术/操作

clinicaltrials.gov NCT07594548

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

适用疾病: Clinical Stage II Esophageal Adenocarcinoma AJCC v8；Clinical Stage III Esophageal Adenocarcinoma AJCC v8；Clinical Stage III Gastric Cancer AJCC v8
干预: Biospecimen Collection，Computed Tomography，Futibatinib，Magnetic Resonance Imaging
地点: United States
申办方: Northwestern University

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT05514769

Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer

适用疾病: Proximal Gastric Adenocarcinoma；Gastric Cancer；Gastroesophageal Reflux Disease
干预: Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty
地点: China
申办方: Nanchong Central Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT06914687

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

适用疾病: Gastric Adenocarcinoma；Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma；Peritoneal Metastasis
干预: Tislelizumab，S-1，Oxaliplatin，Docetaxel
地点: 未列出
申办方: Fudan University

正在招募 Phase 2 药物其他

clinicaltrials.gov NCT06962137

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

适用疾病: Gastric Cancer Adenocarcinoma Metastatic；Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
干预: zolbetuximab，Retrospective cohort, no intervention
地点: Belgium
申办方: Universitaire Ziekenhuizen KU Leuven

正在招募阶段未标明器械手术/操作

clinicaltrials.gov NCT04306458

RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).

适用疾病: Esophageal Adenocarcinoma
干预: Minimally invasive esophagectomy，daVinci Xi system
地点: Germany
申办方: University Medical Center Mainz

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT06926374

Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery

适用疾病: Colorectal Carcinoma；Rectal Prolapse；Prostate Cancer (Adenocarcinoma)
干预: Robotic surgery using the Sentire Surgical System
地点: China
申办方: Chinese University of Hong Kong

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT07622940

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

适用疾病: Recurrent or Metastatic Esophageal Adenocarcinoma；Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease
干预: EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells，Fludarabine，Cyclophosphamide
地点: China
申办方: Beijing Biotech

正在招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT03161522

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

适用疾病: Gastric Adenocarcinoma；Oligometastasis；Stage IV Esophageal Adenocarcinoma AJCC v7
干预: Capecitabine，Chemotherapy，Conventional Surgery，Fluorouracil
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT06824363

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

适用疾病: Solid Tumor, Adult；Malignant Solid Tumor；Stomach Adenocarcinoma
干预: Tremelimumab，Durvalumab
地点: United States
申办方: University of California, Irvine

正在招募 Phase 3 药物

clinicaltrials.gov NCT07152405

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

适用疾病: Gastric Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma
干预: BL-M07D1，Investigator's choice of chemotherapy
地点: China
申办方: Sichuan Baili Pharmaceutical Co., Ltd.

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT05713838

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

适用疾病: Esophagus Adenocarcinoma
干预: Durvalumab，FLOT，mFOLFOX-6，Radiotherapy
地点: Germany
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT06469944

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

适用疾病: Gastroesophageal Junction；Gastroesophageal Adenocarcinoma；Esophageal Neoplasms
干预: Pembrolizumab，Sacituzumab Tirumotecan (sac-TMT)，Capecitabine，Leucovorin
地点: United States，Brazil，Chile，China 等 8 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 药物

clinicaltrials.gov NCT06199895

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

适用疾病: Pancreatic Adenocarcinoma；Cholangiocarcinoma；Lung Cancer
干预: Paclitaxel Polymeric Micelles for Injection
地点: China
申办方: Liu Huang

即将招募 Phase 1 药物

clinicaltrials.gov NCT07643727

Development of Fluorescent Lectin Tracers With Dedicated Technology for in Vivo Detection of Esophageal Dysplasia in Barrett Patients

适用疾病: Barrett's Esophagus With or Without Dysplasia；Barrett Esophagus Adenocarcinoma
干预: WGA-800CW
地点: Netherlands
申办方: University Medical Center Groningen

正在招募 Phase 3 药物

clinicaltrials.gov NCT05188313

TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

适用疾病: Esophageal Cancer；Esophageal Adenocarcinoma
干预: Trastuzumab，Pertuzumab，Paclitaxel，Carboplatin
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

正在招募 Phase 1 药物

clinicaltrials.gov NCT04999761

AB122 Platform Study

适用疾病: Advanced or Metastatic Solid Tumor；Pancreatic Ductal Adenocarcinoma；Colorectal Cancer
干预: AB122，AB122，TAS-116，AB122
地点: Japan
申办方: Taiho Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07481357

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

适用疾病: Gastric (Stomach) Cancer；GastroEsophageal Cancer；Pancreatic Ductal Adenocarcinoma (mPDAC)
干预: DA-3501
地点: South Korea
申办方: Dong-A ST Co., Ltd.

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT07544589

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

适用疾病: Colorectal Cancer；Gastric Adenocarcinoma；Esophageal Adenocarcinoma
干预: DISP-10
地点: United States
申办方: Dispatch Biotherapeutics

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT07001592

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

适用疾病: Gastric Neoplasms；Esophageal Cancer；Liver Cancer
干预: vvDD-hIL-2-RG-1
地点: United States
申办方: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

即将招募 Phase 2 药物

clinicaltrials.gov NCT07689292

Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

适用疾病: Gastric Adenocarcinoma；Gastroesophageal Junction (GEJ) Adenocarcinoma；Gastro-esophageal Junction Adenocarcinoma
干预: Sacituzumab Tirumotecan + Fruquintinib
地点: 未列出
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT07546812

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

适用疾病: HER2-negative；Gastroesophageal Junction；Esophageal Adenocarcinoma
干预: Denikitug，Nivolumab，Ramucirumab，Paclitaxel
地点: Australia
申办方: Gilead Sciences

正在招募 Phase 2 药物

clinicaltrials.gov NCT06687876

Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

适用疾病: Oesophageal Adenocarcinoma；Tumor Microenvironment
干预: Metformin
地点: Netherlands
申办方: Amsterdam UMC, location VUmc

正在招募 Phase 2, Phase 3 药物手术/操作放疗

clinicaltrials.gov NCT07000253

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma

适用疾病: Esophageal Cancer；Gastric (Stomach) Cancer；Gastric Adenocarcinoma
干预: Chemotherapy，Targeted Systemic Therapy，Immunotherapy，Surgery
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

即将招募 Phase 2 其他手术/操作

clinicaltrials.gov NCT07222657

Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma

适用疾病: Esophageal Adenocarcinoma；Esophageal Cancer
干预: Standard of care chemotherapy，LNSC
地点: United States
申办方: Case Comprehensive Cancer Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT06161818

Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

适用疾病: Esophageal Cancer；Adenocarcinoma of the Esophagus
干预: FLOT-CROSS or CROSS-FLOT
地点: Netherlands
申办方: Erasmus Medical Center

正在招募 Phase 1 药物

clinicaltrials.gov NCT04900818

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

适用疾病: Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: TJ033721 (givastomig)，TJ033721 (givastomig) , nivolumab, chemotherapy，TJ033721 (givastomig), chemotherapy，TJ033721 (givastomig), durvalumab, chemotherapy
地点: United States，China
申办方: I-Mab Biopharma US Limited

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT04656041

Folfox+Irinotecan+Chemort In Esophageal Cancer

适用疾病: Gastroesophageal Junction Adenocarcinoma；Esophagogastric Cancer
干预: FOLFOX/ nal-IRI，Paclitaxel，Carboplatin，Proton Radiation Therapy
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 2 诊断检测手术/操作

clinicaltrials.gov NCT07282912

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

适用疾病: Foregut Adenocarcinoma；Esophageal Adenocarcinoma；Gastroesophageal Adenocarcinoma
干预: Sequential cytoreductive intervention，Signatera Genome ultra-sensitive ctDNA blood test
地点: United States
申办方: Yale University

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT03222635

Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma

适用疾病: Submucosal Esophageal Adenocarcinoma；Barrett Esophagus；High-risk Mucosal Esophageal Adenocarcinoma
干预: Endoscopic follow-up
地点: Australia，Belgium，Germany，Netherlands 等 2 个
申办方: Amsterdam UMC

正在招募 Phase 2 药物

clinicaltrials.gov NCT05177133

Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)

适用疾病: Gastric Adenocarcinoma；Esophageal Adenocarcinoma
干预: Capecitabine，Oxaliplatin，Retifanlimab
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06623396

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

适用疾病: Mesothelin Positive；Mesothelin-Expressing Tumors；Esophageal Adenocarcinoma
干预: M28z1XXPD1DNR CAR
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

即将招募 Phase 2 药物

clinicaltrials.gov NCT07507968

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

适用疾病: Esophagogastric Adenocarcinoma
干预: Durvalumab
地点: Germany，Spain
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

即将招募 Phase 2 药物

clinicaltrials.gov NCT06374888

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

适用疾病: Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
干预: Neratinib maleate in combination with capecitabine
地点: 未列出
申办方: Convalife (Shanghai) Co., Ltd.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06628310

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

适用疾病: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma；Esophageal Adenocarcinoma
干预: Telisotuzumab Adizutecan，Budigalimab，Fluorouracil，Leucovorin
地点: United States，Belgium，Canada，China 等 7 个
申办方: AbbVie

正在招募 Phase 2 药物

clinicaltrials.gov NCT06808971

Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ

适用疾病: Gastric Adenocarcinoma；Gastro-esophageal Junction Adenocarcinoma
干预: Adebrelimab, Nab-paclitaxel, Oxaliplatin, Tegafur Gimeracil Oteracil Potassium Capsule
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT06445972

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

适用疾病: Gastroesophageal Junction；Gastroesophageal Adenocarcinoma；Esophageal Neoplasms
干预: Ramucirumab，Paclitaxel，Sacituzumab Tirumotecan，Rescue Medications
地点: United States，Brazil，Chile，China 等 7 个
申办方: Merck Sharp & Dohme LLC

即将招募阶段未标明药物手术/操作

clinicaltrials.gov NCT06836778

Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices

适用疾病: Hepatocellular Carcinoma
干预: Carvedilol Tablets，Endoscopic Variceal Ligation
地点: India
申办方: Institute of Liver and Biliary Sciences, India

正在招募 Phase 2 药物

clinicaltrials.gov NCT06163729

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

适用疾病: Gastroesophageal Junction Adenocarcinoma (Siewert II-III)
干预: Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 3 药物

clinicaltrials.gov NCT07431281

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

适用疾病: Gastric Cancer；Gastroesophageal Junction Adenocarcinoma；Esophageal Cancer
干预: Sonesitatug vedotin，Rilvegostomig，Nivolumab，Capecitabine
地点: United States，Australia，Austria，Belgium 等 18 个
申办方: AstraZeneca

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT04682158

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

适用疾病: Esophageal Adenocarcinoma
干预: Carboplatin，3 Dimensional Conformal Radiation Therapy，Propranolol，Intensity Modulated Radiation Therapy
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 2 药物

clinicaltrials.gov NCT06340711

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

适用疾病: Esophageal Adenocarcinoma；Gastric Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma
干预: OBP-301，Pembrolizumab
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 2 药物

clinicaltrials.gov NCT07432295

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

适用疾病: Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: Givastomig，Nivolumab，5Fluorouracil，Leucovorin
地点: United States，China，Japan
申办方: I-Mab Biopharma US Limited

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

适用疾病: Pancreatic Ductal Adenocarcinoma；Gastric Cancer；Esophageal Cancer
干预: [203Pb]Pb-PSV359，[212Pb]Pb-PSV359
地点: United States
申办方: Perspective Therapeutics

正在招募阶段未标明药物放疗

clinicaltrials.gov NCT06349044

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

适用疾病: Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma；Hepatocellular Carcinoma；Biliary Tract Carcinoma
干预: Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx），Anti-PD-1 monoclonal antibody，Oxaliplatin and Capecitabine，Anti-VEGF 15mg/kg
地点: China
申办方: Zhejiang Cancer Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT07059299

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

适用疾病: Esophagogastric Junction Adenocarcinoma；Gastric Adenocarcinoma；Esophageal Adenocarcinoma
干预: Tislelizumab，FLOT Chemotherapy
地点: Germany
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

正在招募 Phase 2 手术/操作

clinicaltrials.gov NCT06819566

Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC

适用疾病: Hepatocellular Carcinoma；Esophageal Varix；Bleeding Esophageal Varices
干预: Endoscopic variceal ligation (EVL)
地点: South Korea
申办方: Asan Medical Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT06250036

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

适用疾病: Locally Advanced Gastric Adenocarcinoma；MSI-H/dMMR Gastric Cancer；MSI-H/dMMR Gastroesophageal-junction Cancer
干预: Single agent zimberelimab，Combination zimberelimab + domvanalimab
地点: United Kingdom
申办方: Royal Marsden NHS Foundation Trust

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT06532799

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

适用疾病: Stomach Cancer；Stomach Cancer Recurrent；Stomach Cancer, Adenocarcinoma
干预: Tumor Infiltrating Lymphocytes (TIL)，Cyclophosphamid，Fludarabine，Interleukin-2
地点: China
申办方: Essen Biotech

正在招募 Phase 1 药物其他放疗

clinicaltrials.gov NCT04615013

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

适用疾病: Cervical Esophagus Adenocarcinoma；Clinical Stage II Esophageal Adenocarcinoma AJCC v8；Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8
干预: Capecitabine，Carboplatin，Docetaxel，Fluorouracil
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT07680569

Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma

适用疾病: GC/GEJC
干预: Zolbetuximab，Oxaliplatin + 5-Fluorouracil/Leucovorin，CAPOX (oxaliplatin/capecitabine)
地点: 未列出
申办方: Kaohsiung Medical University Chung-Ho Memorial Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06005493

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

适用疾病: Gastric Cancer；Gastro-esophageal Junction Cancer；Pancreatic Ductal Adenocarcinoma
干预: AZD5863
地点: United States，China，France，Japan 等 4 个
申办方: AstraZeneca

正在招募 Phase 1 药物

clinicaltrials.gov NCT06266299

A Study of KK2269 in Adult Participants With Solid Tumors

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Gastric Adenocarcinoma
干预: KK2269，Docetaxel
地点: United States，Japan
申办方: Kyowa Kirin Co., Ltd.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06008054

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

适用疾病: Esophageal Cancer；Gastric Cancer；Colorectal Cancer
干预: SI-B003，BL-B01D1，PD-1 Monoclonal Antibody
地点: China
申办方: Sichuan Baili Pharmaceutical Co., Ltd.

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT07071103

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

适用疾病: Radiotherapy；Metastatic Solid Cancers；Immune Checkpoint Blockade
干预: Low-dose radiotherapy to the intestine (ILDR)，PD-1/PD-L1 monoclonal antibodies
地点: China
申办方: Chuangzhen Chen

即将招募 Phase 1, Phase 2 药物手术/操作

clinicaltrials.gov NCT07594626

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

适用疾病: Metastatic Biliary Tract Carcinoma；Metastatic Colon Carcinoma；Metastatic Esophageal Carcinoma
干预: Biospecimen Collection，Computed Tomography，Pemetrexed，PRMT5 Inhibitor BMS-986504
地点: United States
申办方: Northwestern University

即将招募 Phase 2 药物放疗

clinicaltrials.gov NCT05628610

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

适用疾病: Esophageal Cancer
干预: Tislelizumab，Radiation，Paclitaxel，Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs
地点: 未列出
申办方: Fujian Cancer Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

适用疾病: Advanced Solid Tumor；Melanoma；Head and Neck Cancer
干预: HER3-DXd
地点: United States，Australia，Belgium，Canada 等 12 个
申办方: Daiichi Sankyo

即将招募 Phase 2 药物

clinicaltrials.gov NCT07126561

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

适用疾病: HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
干预: Trastuzumab Deruxtecan
地点: 未列出
申办方: University of Chicago

正在招募 Phase 2 生物制剂药物放疗

clinicaltrials.gov NCT06084897

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

适用疾病: Esophageal Neoplasm Metastatic；Esophageal Cancer Stage IVb
干预: TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.，PD-1 inhibitor，Consolidation Radiation，Salvage Radiation
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 1 药物

clinicaltrials.gov NCT07181473

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

适用疾病: Lung Cancer (NSCLC)；Prostate Cancer；Esophageal Cancer
干预: TJ101
地点: United States，China
申办方: Phrontline Biopharma

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06474468

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer

适用疾病: Advanced or Metastatic Esophageal Cancer
干预: SHR-A2102；Adebrelimab；Cisplatin
地点: China
申办方: Shanghai Hengrui Pharmaceutical Co., Ltd.

正在招募 Phase 3 生物制剂药物放疗

clinicaltrials.gov NCT06086457

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

适用疾病: Esophageal Neoplasms
干预: Radiation，TP or PF regimen depended on investigator's choice.，PD-1 inhibitor
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 1 药物

clinicaltrials.gov NCT06500052

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

适用疾病: Esophageal Cancer；Gastric Cancer；Pancreatic Cancer
干预: BL-M17D1
地点: China
申办方: Sichuan Baili Pharmaceutical Co., Ltd.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07367516

Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer

适用疾病: Esophageal Cancer
干预: TQB6411 Injection
地点: China
申办方: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07410676

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

适用疾病: Cancer；Sarcoma；Leukaemia
干预: EBNK-001 + IL-15 + Pembrolizumab
地点: China
申办方: Essen Biotech

正在招募 Phase 4 药物

clinicaltrials.gov NCT05183126

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

适用疾病: Breast Cancer；Metastatic Gastric Cancer；Esophageal Cancer
干预: Paclitaxel，Paclitaxel
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05187338

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

适用疾病: Lung Cancer；Liver Cancer；Colorectal Cancer
干预: ipilimumab +pembrolizumab +durvalumab
地点: China
申办方: Second Affiliated Hospital of Guangzhou Medical University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05944237

HTL0039732 in Participants With Advanced Solid Tumours

适用疾病: Neoplasms；Prostatic Neoplasms, Castration-Resistant；Stomach Neoplasms
干预: HTL0039732 Capsules，HTL0039732 Capsules and atezolizumab infusion
地点: United Kingdom
申办方: Cancer Research UK

术语	中文意思	对找临床试验有什么用
食管鳞癌 / ESCC	中国较常见的食管癌病理类型。	海外试验常区分 squamous cell carcinoma 和 adenocarcinoma。
食管腺癌 / Esophageal adenocarcinoma	另一类食管癌病理类型，在欧美较常见。	如果病理是腺癌，搜索时要加 adenocarcinoma。
PD-L1	和免疫治疗相关的生物标志物。	免疫治疗试验可能要求 PD-L1 表达或按表达分层。
Chemoradiation	同步或序贯放化疗，常见于局部晚期治疗路径。	试验可能限定既往是否接受过放化疗。
转移性食管癌 / metastatic esophageal cancer	癌症已扩散到远处器官或淋巴结。	很多系统治疗试验会限定 metastatic 或 advanced 患者。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

食管癌

当前同步到的治疗类试验